Chinese
Home
About Livzon
Milestones
Leaders' Caring
Company Honors
Cultural Vision
Contact Us
Media
Livzon News
Employment system
Investor Relations
Company Governance
Announcement
Financial Reports
ESG Report
Shareholder Returns
Stock Information
Sustainable Development
Human Development
Board Diversity Policy
Business Ethics
Supplier
Environment, Occupational Health and Safety (EHS)
Philanthropy
Privacy Policy
Tax policy
ESG Ratings and Honors
Product
Leading Products
Products List
ADR Reporting
R&D
R&D Platforms
Livzon microspheres
Livzon Bio
Livzon Research Institute
R&D Achievements
IP Achievements
Overseas Market
Overseas Business
Specialty Products
Certificates
Contact us
Join Us
Social Recruitment
Campus Recruitment
Compensation and Benefits
Appeal Against
Bidding procurement
Tender Announcement
Supplier Login
Supervision and Reporting
Contact information
Online message
ESG report
Shareholder returns
Stock information
Contacts
2026
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Next Day Disclosure Return
File size:
96.7KB
File Type:
pdf
2025-07-31
96.6KB
2025-07-30
96.5KB
2025-07-29
96.4KB
2025-07-28
VOLUNTARY ANNOUNCEMENT ACHIEVEMENT OF THE PRIMARY ENDPOINT IN PHASE III CLINICAL TRIAL OF RECOMBINANT ANTI-HUMAN IL-17A/F HUMANIZED MONOCLONAL ANTIBODY INJECTION
129.5KB
2025-07-21
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
65.9KB
2025-07-01
VOLUNTARY ANNOUNCEMENT THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF YJH-012 INJECTION
172.0KB
2025-06-24
Overseas Regulatory Announcement
183.1KB
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
68.4KB
2025-06-03
Final Dividend for the year ended 31 December 2024 (Update)
43.2KB
2025-05-29
